ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered
adjunctively to current therapy in reducing seizure frequency in patients diagnosed with
focal (partial onset) epilepsy and treated with 1 to 4 antiseizure medications yet still
experiencing seizures.